Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Land & Improvements (2016 - 2025)

Pediatrix Medical (MD) has disclosed Land & Improvements for 15 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Land & Improvements changed 0.0% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.0 million, a 0.0% change, with the full-year FY2025 number at $2.0 million, changed 0.0% from a year prior.
  • Land & Improvements was $2.0 million for Q4 2025 at Pediatrix Medical, roughly flat from $2.0 million in the prior quarter.
  • In the past five years, Land & Improvements ranged from a high of $2.0 million in Q4 2021 to a low of $2.0 million in Q4 2021.
  • A 5-year average of $2.0 million and a median of $2.0 million in 2021 define the central range for Land & Improvements.
  • Peak YoY movement for Land & Improvements: tumbled 69.59% in 2021, then changed 0.0% in 2022.
  • Pediatrix Medical's Land & Improvements stood at $2.0 million in 2021, then changed by 0.0% to $2.0 million in 2022, then changed by 0.0% to $2.0 million in 2023, then changed by 0.0% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for MD's Land & Improvements are $2.0 million (Q4 2025), $2.0 million (Q4 2024), and $2.0 million (Q4 2023).